Brian Singerman

Brian Singerman is a partner at Founders Fund, a San Francisco-based venture capital firm with over $11 billion under management.

Singerman graduated from Stanford University in 1999 with a B.S. in Computer Science. Following Stanford, Singerman joined the virtual-world online start-up, There, as a software engineer. In 2004, Singerman joined Google. He spent the next four years there as an engineer and executive and founded the personal web portal, iGoogle.

While at Google, Singerman started his career as an investor, launching a $1 million fund called XGYC Fund, short for "ex-Google, Y Combinator. In 2008, Singerman joined Founders Fund where he serves as a partner along with Peter Thiel and Ken Howery. Among other industries, he focuses on healthcare, biotech, wearable computing and robotics. Singerman is a board director for Affirm, AltSchool, Cloud9, Emerald Therapeutics, The Long-Term Stock Exchange, Oscar Health and Postmates, and a board observer for Airbnb, Forward and Wish.

In April 2016, Singerman's largest investment to date, Stemcentrx, was acquired by pharmaceutical company AbbVie in a transaction valuing the company at up to $10.2 billion. The acquisition was the largest portfolio exit in the history of Founders Fund. Stemcentrx was shuttered in 2019 when its cancer drug, Rova-T, failed to outperform placebo in a Phase 3 clinical trial.